TAYLOR GLEN A 4
4 · Envoy Medical, Inc. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Envoy Medical (COCH) 10% Owner Glen A. Taylor Buys Stock
What Happened
Glen A. Taylor (reported as a 10% owner; owner and chairman of Taylor Sports Group) purchased 18,750,000 Envoy Medical (COCH) shares on Feb 12, 2026 at $0.40 per share for a total cash outlay of $7,500,000. On the same date he also acquired two derivative positions totaling 30,000,000 shares at $0.00 (these represent Common Warrants/derivative securities rather than immediate-paid shares).
Key Details
- Transaction date: Feb 12, 2026; Form 4 filed Feb 17, 2026 (period of report: 2026-02-12).
- Cash purchase: 18,750,000 shares @ $0.40 = $7,500,000 (transaction code P = Purchase).
- Derivative acquisitions: 11,250,000 shares @ $0.00 and 18,750,000 shares @ $0.00 (transaction code P but reflect derivative/warrant issuance).
- Ownership after transaction: Not specified in the filing.
- Related parties: Filing notes the reporting person is owner/chairman of Taylor Sports Group (F1) and controls GAT Funding, LLC (F2).
- Warrant specifics: The acquired Common Warrants become exercisable upon the stockholder approval date (F3). Series A‑1 Warrants expire the earlier of 24 months after stockholder approval or 30 days after the company publicly announces submission of a PMA for its Acclaim cochlear implant (F4). Series A‑2 Warrants expire the earlier of 60 months after stockholder approval or 30 days after FDA approval for Acclaim (F5).
Context
This filing shows a meaningful cash purchase by a 10% owner (often more institutionally driven than routine executive trading) plus receipt of warrant/derivative securities that are contingent on future stockholder approval and regulatory milestones. The $7.5M cash purchase is the most concrete bullish signal in the report; the $0.00 entries reflect derivative instruments with exercise and expiration conditions rather than immediate-share purchases.
Insider Transaction Report
- Purchase
Class A Common Stock
2026-02-12$0.40/sh+18,750,000$7,500,000→ 21,703,607 total - Purchase
Warrant Shares (Series A-1)
[F3][F4]2026-02-12+11,250,000→ 11,250,000 totalExercise: $0.40→ Class A Common Stock (11,250,000 underlying) - Purchase
Warrant Shares (Series A-2)
[F3][F5]2026-02-12+18,750,000→ 18,750,000 totalExercise: $0.40→ Class A Common Stock (18,750,000 underlying)
- 2,526,058(indirect: By Taylor Sports Group)
Class A Common Stock
[F1] - 4,810,384(indirect: By LLC)
Class A Common Stock
[F2]
Footnotes (5)
- [F1]The Reporting Person is the owner and chairman of Taylor Sports Group.
- [F2]GAT Funding, LLC is an entity controlled by Reporting Person.
- [F3]The Series A-1 Warrants and Series A-2 Warrants (the "Common Warrants") will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Common Warrants (the "Stockholder Approval Date").
- [F4]The Series A-1 Warrants expire on the earlier of (i) the twenty-four month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for its Acclaim cochlear implant (the "Series A-1 Milestone Event").
- [F5]The Series A-2 Warrants expire on the earlier of (i) the sixty-month anniversary of the Stockholder Approval Date and (ii) thirty days following the date the Company publicly announces that it has received U.S. Food and Drug Administration approval for its Acclaim cochlear implant (the "Series A-2 Milestone Event").